Bio-Rad Laboratories QX Continuum and QX700 series ddPCR platforms

Bio-Rad Laboratories has launched its four latest Droplet Digital PCR (ddPCR) platforms. The instruments include Bio-Rad’s QX Continuum ddPCR system along with the QX700 series of ddPCR platforms, acquired as part of the company’s recently completed acquisition of digital PCR developer Stilla Technologies.

The QX Continuum ddPCR system is designed for translational research applications. It features qPCR-like workflow offering simplicity, performance and flexibility in an all-in-one configuration with four-colour multiplexing and up to eight discrete thermal profiles per plate.

The QX700 series consists of three ddPCR instruments designed for academic research, environmental testing, cell and gene therapy, and biopharma quality control workflows. The systems enable seven-colour multiplexing, the capacity to process over 700 samples per day with minimal input volume, continuous loading capability, and easy-to-use software for streamlined data interpretation.

The latest platforms complement Bio-Rad’s existing QX ddPCR portfolio and offer users workflow simplicity and throughput capabilities across the full spectrum of digital PCR applications, including oncology, infectious disease and genetic research. The company’s expanded product portfolio thus offers a comprehensive line of digital PCR products for life science research and diagnostic applications.